FDA Clears QUELIMMUNE Post-Approval Study Requirement, Opening Therapy to More Pediatric Centers
ICU sits 16% above its 52-week low of $2.07.
Summary
FDA's CBER determined the QUELIMMUNE Pediatric SAVE Registry satisfied the post-approval study obligations tied to the February 2024 Humanitarian Device Exemption approval. The practical effect: hospitals can now use QUELIMMUNE without the research infrastructure the registry required, widening the pool of pediatric centers that can offer the therapy. This builds on the SAVE Registry data presented at ASN Kidney Week 2026, which showed 65.1% 90-day survival for QUELIMMUNE patients (N=43) versus 47.5% for clinically aligned KID cohorts (N=196, P=0.043), with no device-related adverse events. For a company with a roughly $10M market cap, a $0.6M quarterly revenue base and going-concern doubt flagged in the Q2 10-Q, removing an adoption barrier is the most direct route to incremental revenue. The October warrant inducement raised $3.3M and the S-3 registered the underlying shares, so the balance sheet remains thin. Watch the adult NEUTRALIZE-AKI pivotal trial in 339 patients as the larger value driver.
At the time of this announcement, ICU was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $2.07 to $6.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.